Celularity Inc (CELU) Stock Analysis
Verdict: AVOID
A $300M manufacturing deal triggered a 138% rally, but cash burn ($13.3M/yr) and negative equity (-$38.1M) pose severe dilution risk.
Investment score: 36/100
Analysis as of
Is Celularity Inc stock worth reviewing? AI model thesis
The model sees Celularity as a high-risk micro-cap where catalyst-driven momentum is overshadowed by acute capital distress and imminent dilution risk.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Celularity Inc opportunities and risks
What speaks for CELU
- MuseCell Manufacturing Expansion ($300M+ Potential Revenue)
What speaks against CELU
- Severe Cash Depletion and Imminent Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CELU | n/a | 2.3x | n/a | 76.0% | -345.4% | -21.8% |
| NXTC | n/a | 0.0x | n/a | 0.0% | 0.0% | -169.7% |
| SHPH | n/a | 0.0x | n/a | 0.0% | 0.0% | -412.8% |
| ATOS | n/a | 0.0x | n/a | 0.0% | 0.0% | -135.9% |
| BYSI | n/a | 0.0x | n/a | 0.0% | 0.0% | -64.8% |
| IMUC | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.9% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -135.9% |
Frequently asked questions about Celularity Inc (CELU)
Is CELU stock a good investment?
The cached TradeMates AI model rates Celularity Inc as AVOID with an investment score of 36/100. The model sees Celularity as a high-risk micro-cap where catalyst-driven momentum is overshadowed by acute capital distress and imminent dilution risk. This is algorithmic model output, not personal investment advice.
Is CELU stock a buy?
The TradeMates model verdict for CELU is AVOID with an investment score of 36/100. Treat this as a model signal to review, not a personal buy recommendation.